Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...

In the latest market close, Gilead Sciences (GILD) reached $98.38, with a +1.21% movement compared to the previous day. The stock outpaced the S&P 500's daily loss of 0.76%. Elsewhere, the Dow saw a ...

With a market cap of $121,1 billion, Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company specializing in the ...

Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver ...

Bonus Apr 08, 1994 May 03, 1994 Mar 24, 1994 Bonus Ratio: 2 share(s) for every 1 shares held Bonus Dec 04, 1992 Dec 22, 1992 Sep 30, 1992 Bonus Ratio: 1 share(s) for every 1 shares held Dr. Reddy's ...